Your browser is no longer supported. Please, upgrade your browser.
Settings
EIGR Eiger BioPharmaceuticals, Inc. daily Stock Chart
EIGR [NASD]
Eiger BioPharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.87 Insider Own2.09% Shs Outstand13.64M Perf Week23.41%
Market Cap163.95M Forward P/E- EPS next Y-2.67 Insider Trans0.00% Shs Float13.64M Perf Month0.17%
Income-38.80M PEG- EPS next Q-0.74 Inst Own75.50% Short Float0.97% Perf Quarter11.30%
Sales- P/S- EPS this Y38.00% Inst Trans-0.09% Short Ratio1.55 Perf Half Y15.02%
Book/sh4.09 P/B2.94 EPS next Y11.30% ROA-83.60% Target Price30.14 Perf Year3.18%
Cash/sh5.39 P/C2.23 EPS next 5Y- ROE-156.70% 52W Range7.46 - 18.00 Perf YTD-13.84%
Dividend- P/FCF- EPS past 5Y19.30% ROI- 52W High-34.06% Beta1.89
Dividend %- Quick Ratio8.50 Sales past 5Y- Gross Margin- 52W Low59.12% ATR0.73
Employees16 Current Ratio8.50 Sales Q/Q- Oper. Margin- RSI (14)55.16 Volatility9.21% 6.25%
OptionableNo Debt/Eq0.41 EPS Q/Q38.20% Profit Margin- Rel Volume1.31 Prev Close12.02
ShortableYes LT Debt/Eq0.34 EarningsNov 09 AMC Payout- Avg Volume85.77K Price11.87
Recom1.30 SMA203.56% SMA501.72% SMA2007.51% Volume81,402 Change-1.25%
May-09-18Initiated B. Riley FBR, Inc. Buy $24
Jan-03-18Initiated Ladenburg Thalmann Buy $32
Oct-19-17Initiated ROTH Capital Buy $35
Jun-21-17Resumed Wedbush Outperform $28 → $34
Oct-18-18 08:00AM  Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference PR Newswire
07:56AM  The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs Benzinga
Oct-17-18 04:05PM  Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection PR Newswire +7.36%
08:15AM  The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise Benzinga
Oct-16-18 04:05PM  Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH) PR Newswire +7.09%
04:05PM  Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint PR Newswire
Sep-25-18 08:00AM  Eiger BioPharmaceuticals to Participate in Investor Conferences PR Newswire
Sep-24-18 08:00AM  Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018 PR Newswire
Aug-27-18 08:00AM  Eiger BioPharmaceuticals to Participate in Investor Conferences PR Newswire
Aug-13-18 08:00AM  Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia PR Newswire
Aug-10-18 08:09AM  Eiger BioPharma: 2Q Earnings Snapshot Associated Press
08:00AM  Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results PR Newswire
Aug-07-18 08:00AM  Eiger BioPharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-06-18 08:00AM  Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health PR Newswire
Jul-31-18 08:00AM  Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection PR Newswire
Jul-19-18 07:26AM  Eiger BioPharmaceuticals (EIGR) Enters Oversold Territory Zacks
05:51AM  Eiger BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-04-18 08:00AM  Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018 PR Newswire +8.00%
May-30-18 08:00AM  Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference PR Newswire
May-24-18 09:05AM  Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PR Newswire -6.09%
08:37AM  Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings Benzinga
May-23-18 04:15PM  Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
May-18-18 08:10AM  Todays Research Reports on Stocks to Watch: Eiger BioPharmaceuticals and Nektar Therapeutics ACCESSWIRE -17.26%
May-16-18 08:00AM  Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals PR Newswire +8.22%
08:00AM  Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF) PR Newswire
May-11-18 08:09AM  Eiger BioPharma: 1Q Earnings Snapshot Associated Press +8.11%
08:00AM  Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results PR Newswire
Apr-17-18 10:31AM  Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress 2018 PR Newswire
Apr-02-18 08:00AM  Eiger BioPharmaceuticals to Participate in Conferences in April PR Newswire
Mar-29-18 07:59PM  What Should We Expect From Eiger BioPharmaceuticals Incs (NASDAQ:EIGR) Earnings In The Next Couple Of Years? Simply Wall St. +5.35%
Mar-26-18 08:00AM  Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia PR Newswire
Mar-23-18 07:00AM  Wired News FDA Permitted a Single Registration Trial Assessing Eiger BioPharmas Lonafarnib in HDV to Support NDA Filing ACCESSWIRE
Mar-21-18 08:00AM  Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program PR Newswire
Mar-12-18 08:13AM  Eiger BioPharma reports 4Q loss Associated Press -8.21%
08:00AM  Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results PR Newswire
Mar-06-18 08:00AM  Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March PR Newswire
Mar-05-18 08:00AM  Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress Meeting PR Newswire
Feb-06-18 08:00AM  Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February PR Newswire
Jan-23-18 11:30AM  3 Pharma and Biotech Stocks to Watch Out for in 2018 InvestorPlace
Jan-19-18 08:54AM  These Two Biotechs Just Reported Key Data Market Exclusive
Jan-16-18 10:45AM  Why Eiger BioPharma Shares Are Getting Crushed 24/7 Wall St. -49.37%
08:54AM  Eiger shares plummet 40% after phase 2 trial failure MarketWatch
08:00AM  Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint PR Newswire
Jan-08-18 08:00AM  Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors PR Newswire
Jan-04-18 08:00AM  Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients PR Newswire
Jan-03-18 08:00AM  Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer PR Newswire
Jan-02-18 08:00AM  Eiger BioPharmaceuticals to Present at Biotech Showcase 2018 PR Newswire
Dec-22-17 08:57AM  Why Eiger BioPharmaceuticals (EIGR) Could Be Positioned for a Surge Zacks
Nov-13-17 08:00AM  Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference PR Newswire
Nov-09-17 08:39AM  Eiger BioPharma reports 3Q loss Associated Press
08:00AM  Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results PR Newswire
Nov-07-17 06:48PM  Should Your Next Investment In The Healthcare Industry Be In Eiger BioPharmaceuticals Inc (EIGR)? Simply Wall St. -6.19%
Nov-06-17 08:00AM  Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire
07:42AM  Does Eiger BioPharmaceuticals Incs (EIGR) Debt Level Pose A Serious Problem? Simply Wall St.
Oct-31-17 04:11PM  Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter's Option to Purchase Additional Shares PR Newswire
Oct-27-17 09:17AM  Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire +7.41%
Oct-26-17 04:30PM  Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
Oct-23-17 08:00AM  Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) Meeting PR Newswire -6.25%
Oct-02-17 08:00AM  Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting PR Newswire +6.36%
Sep-18-17 08:00AM  Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors PR Newswire
Sep-05-17 08:00AM  Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PR Newswire
Aug-30-17 08:00AM  Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences PR Newswire +9.39%
Aug-14-17 11:22PM  Eiger BioPharma reports 2Q loss Associated Press
08:00AM  Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results PR Newswire
Aug-08-17 08:00AM  Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th PR Newswire
Jul-27-17 08:00AM  Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PR Newswire
Jul-24-17 08:00AM  Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PR Newswire
Jul-17-17 08:30AM  Eiger BioPharmaceuticals (EIGR) Rises: Stock Climbs 24% Zacks +7.57%
Jun-29-17 08:00AM  Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals PR Newswire +10.71%
Jun-14-17 08:00AM  Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors PR Newswire
Jun-12-17 08:00AM  Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego PR Newswire
Jun-06-17 08:00AM  Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients PR Newswire
May-30-17 08:00AM  Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th PR Newswire
May-17-17 08:00AM  Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema PR Newswire
May-15-17 08:00AM  Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension PR Newswire
May-12-17 08:15AM  Eiger BioPharma reports 1Q loss Associated Press -6.62%
08:00AM  Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results PR Newswire
May-08-17 08:00AM  Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago PR Newswire
May-04-17 08:00AM  Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City PR Newswire
May-03-17 08:00AM  Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection PR Newswire
Apr-30-17 02:00PM  2 'Swing for the Fences' Small Biotechs TheStreet.com
Apr-24-17 08:00AM  Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago PR Newswire
Apr-21-17 08:00AM  Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress 2017 PR Newswire
Apr-18-17 08:00AM  Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia PR Newswire
Apr-06-17 08:00AM  Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting PR Newswire -15.74%
Mar-28-17 01:04PM  EIGER BIOPHARMACEUTICALS, INC. Financials
09:50AM  New Strong Buy Stocks for March 28th
Mar-23-17 08:10AM  Eiger BioPharma reports 4Q loss Associated Press
08:04AM  EIGER BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
08:00AM  Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results PR Newswire
06:06AM  EIGER BIOPHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-06-17 08:00AM  Eiger BioPharmaceuticals to Present at the ROTH and Oppenheimer Investor Conferences in March 2017 PR Newswire
Jan-30-17 08:00AM  Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th PR Newswire
Jan-05-17 04:08PM  EIGER BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct F
Jan-04-17 08:00AM  Eiger Completes $25 Million Debt Financing with Oxford Finance PR Newswire
Jan-03-17 08:00AM  Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH) PR Newswire
Dec-14-16 06:21PM  How Five Star Quality Care, Inc. (FVE) Stacks Up Against Its Peers Insider Monkey
Dec-12-16 08:00AM  Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH) PR Newswire
Dec-01-16 08:44AM  Eiger BioPharmaceuticals, Inc. :EIGR-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 Capital Cube
Nov-29-16 08:00AM  Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH) PR Newswire
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Quan JoanneChief Medical OfficerApr 02Option Exercise2.064,0008,2404,000Apr 04 05:18 PM
Quan JoanneChief Medical OfficerApr 02Sale10.004,00040,0000Apr 04 05:18 PM